Technical Analysis for IFRX - InflaRx N.V.
|Grade||Last Price||% Change||Price Change|
IFRX closed up 4.39 percent on Friday, April 20, 2018, on 87 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical IFRX trend table...|
|Date||Alert Name||Type||% Chg|
|Apr 20||New 52 Week Closing High||Bullish||0.00%|
|Apr 20||New 52 Week High||Strength||0.00%|
|Apr 20||Upper Bollinger Band Walk||Strength||0.00%|
|Apr 20||Wide Bands||Range Expansion||0.00%|
|Apr 20||Above Upper BB||Strength||0.00%|
|Apr 20||Overbought Stochastic||Strength||0.00%|
|Apr 20||Up 3 Days in a Row||Strength||0.00%|
|Apr 20||Up 4 Days in a Row||Strength||0.00%|
|Apr 20||Up 5 Days in a Row||Strength||0.00%|
|Apr 20||Upper Bollinger Band Touch||Strength||0.00%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more IFRX news...
|52 Week High||39.0|
|52 Week Low||14.47|
|200-Day Moving Average||0.0|
|50-Day Moving Average||30.0422|
|20-Day Moving Average||31.6765|
|10-Day Moving Average||34.301|
|Average True Range||2.4353|
|Chandelier Exit (Long, 3 ATRs )||31.6941|
|Chandelier Exit (Short, 3 ATRs )||33.7659|
|Upper Bollinger Band||38.4879|
|Lower Bollinger Band||24.8651|
|Percent B (%b)||1.02|
|MACD Signal Line||1.4008|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||41.08|
|Resistance 3 (R3)||40.90||39.95||40.70|
|Resistance 2 (R2)||39.95||39.36||40.04||40.57|
|Resistance 1 (R1)||39.36||39.00||39.66||39.54||40.44|
|Support 1 (S1)||37.82||37.82||38.12||38.00||37.10|
|Support 2 (S2)||36.87||37.46||36.96||36.97|
|Support 3 (S3)||36.28||36.87||36.85|
|Support 4 (S4)||36.46|